What Diacerein Is
Diacerein is a synthetic anthraquinone derivative used as an active pharmaceutical ingredient in the treatment of osteoarthritis. Its CAS registry number is 13739-02-1, its molecular formula is C19H12O8 and its molecular weight is 368.3 g per mole. Chemically it is the diacetyl ester of rhein, and it is this ester that makes the molecule a prodrug: after absorption it is deacetylated to rhein, the metabolite that carries the pharmacological activity. The raw material is a yellow, crystalline powder that is practically insoluble in water, a property that shapes both its formulation strategy and the analytical methods used to control it.
In pharmacopoeial and trade documentation the substance is listed under its international nonproprietary name, diacerein, with monographs published in the British Pharmacopoeia, the European Pharmacopoeia and the United States Pharmacopoeia frameworks and with limits agreed between buyer and supplier for related substances, residual solvents and heavy metals.
How Diacerein Works
Osteoarthritis is driven by an imbalance between the breakdown and the repair of articular cartilage. Diacerein and its rhein metabolite act on that balance from the repair side. The metabolite inhibits the activity of interleukin-1, a cytokine that pushes cartilage cells towards degradation, and it down-regulates the metalloproteinases and other enzymes that digest the collagen matrix. At the same time it stimulates the synthesis of proteoglycans and collagen by chondrocytes, which is why it is described as a proteoglycan synthesis stimulator. The net effect on the joint is slower cartilage loss, better maintenance of the matrix and a reduction in the pain and swelling that accompany the disease.
One practical consequence of this mechanism is that diacerein is not a rapid analgesic. Its benefit builds over weeks of continuous treatment, which places it in the group of slow-acting, symptom-modifying drugs for osteoarthritis rather than among immediate pain relievers. Because its action does not depend on the same pathway as conventional anti-inflammatory drugs, it is usually described as sparing the gastric irritation associated with long-term use of nonsteroidal anti-inflammatory drugs.
Main Therapeutic Uses
Osteoarthritis of the knee and hip - the core indication, where diacerein is used to slow cartilage degradation and to reduce pain and joint inflammation during long-term treatment.
Joint protection - by promoting collagen synthesis and inhibiting cartilage-destroying enzymes, it supports joint health and mobility alongside symptom relief.
Anti-inflammatory effect without gastric irritation - useful for patients who cannot tolerate nonsteroidal anti-inflammatory drugs, since the anti-inflammatory action does not rely on cyclo-oxygenase inhibition.
Investigational use in inflammatory joint disease - although osteoarthritis is the established indication, published studies have examined whether patients with rheumatoid arthritis may also benefit from the drug.
Quality, Handling and Regulatory Context
As a pharmaceutical ingredient, diacerein is bought against a pharmacopoeial monograph or an agreed in-house specification and is released on the strength of a certificate of analysis covering identity, assay, related substances, residual solvents, water content, heavy metals and physical form. Particle size and polymorphic form deserve attention at the development stage, because the low aqueous solubility of the material makes dissolution rate sensitive to both. Handling requirements follow the safety data sheet: ventilated areas, dust control, gloves and eye protection for operators, and storage in tight, light-resistant containers in a dry place.
Regulatory status varies between markets. In several countries diacerein is a prescription medicine subject to restricted use or additional monitoring because of gastrointestinal and hepatic safety concerns, while in others it remains a standard option in the osteoarthritis formulary. Buyers therefore need to confirm that the grade on offer is supported by the documentation their own market requires, including registration support where applicable.
Frequently Asked Questions
Q: What is diacerein used for?
It is used in the treatment of osteoarthritis, chiefly of the knee and hip, to slow cartilage degradation and to reduce joint pain and inflammation.
Q: What is the CAS number of diacerein?
The CAS registry number is 13739-02-1, corresponding to the diacetylated ester of rhein with the formula C19H12O8.
Q: How does diacerein differ from an ordinary anti-inflammatory drug?
It acts by stimulating proteoglycan and collagen synthesis and by inhibiting interleukin-1 rather than by blocking cyclo-oxygenase, so it is not a rapid painkiller and does not carry the classic gastric irritation profile.
Q: Is diacerein a prodrug?
Yes. The intact molecule is largely deacetylated after absorption, and the active metabolite that reaches the joint tissue is rhein.
Q: Which pharmacopoeial monographs cover diacerein?
Monographs are published in the British, European and United States Pharmacopoeia frameworks, and trade orders normally reference the applicable monograph together with any tighter in-house specification.
Q: What documentation should accompany a diacerein shipment?
A batch certificate of analysis against the agreed specification, the safety data sheet, and registration or regulatory support documents where the destination market requires them.





